Komiotis D, Wencel-Drake J D, Dieter J P, Lim C T, Le Breton G C
Department of Pharmacology, University of Illinois at Chicago 60612, USA.
Biochem Pharmacol. 1996 Sep 13;52(5):763-70. doi: 10.1016/0006-2952(96)00359-0.
This study reports the synthesis, biological evaluation, and application of a new biotinylated derivative 1-[[1S-[1 alpha, 2 alpha (Z),3 alpha, 4 alpha]]-7-[3-[[[[(1-oxocyclohexylpropyl)amino]acetyl]amino] methyl]-7-oxabicyclo [2.2.1]hept-2-yl]-5-heptenoyl]-2-[hexahydro-2'-oxo-1H-thieno[3',4' d] imidazole-4'-pentanoyl]hydrazine (SQB) of the thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist [1S-[1 alpha,2 alpha(Z),3 alpha,4 alpha]]-7-[3-[[[[(1-oxocyclohexylpropyl)amino]acetyl] amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (SQ31,491). SQB was synthesized by reacting SQ31,491 with biotin hydrazide, and the product was purified by flash chromatography. It was found that SQB specifically inhibited platelet aggregation in response to U46619 with an IC50 of 275 nM. On the other hand, SQB did not inhibit adenosine diphosphate or A23187-induced aggregation. Competition binding studies revealed that SQB produced a concentration-dependent inhibition of [3H]-[1S-[1 alpha, 2 beta (5Z),3 beta, 4 alpha]]-7-[3-[[2[(phenylamino) carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid ([3H]SQ29,548) specific binding in 3-[(3-cholamidopropyl)dimethylammonio]-1-propane-sulfonate (CHAPS)-solubilized platelet membranes, with a Ki of 220 nM. The shape of the SQB inhibition binding curve was indistinguishable from that produced by the TXA2/PGH2 receptor antagonist BM13.177. Finally, incubation of gel-filtered platelets or platelet-rich plasma with SQB and fluorescein isothiocyanate (FITC)-avidin demonstrated fluorescent labeling of platelet plasma membrane TXA2/PGH2 receptors. Furthermore, this SQB-FITC fluorescent labeling was reduced significantly by co-incubation of the platelets with the TXA2/PGH2 antagonist SQ29,548. Based on the ability of SQB-FITC-avidin to label intact platelets, it can be concluded: (1) that a pool of platelet TXA2/PGH2 receptors resides in the plasma membrane; and (2) that the binding domains for these receptors are oriented at or near the external membrane surface. Collectively, these data demonstrate that SQB is a highly specific probe for TXA2/PGH2 receptors, which should be of significant value for receptor localization studies in platelets and other tissues.
本研究报告了血栓素A2/前列腺素H2(TXA2/PGH2)受体拮抗剂[1S-[1α,2α(Z),3α,4α]]-7-[3-[[[[(1-氧代环己基丙基)氨基]乙酰基]氨基]甲基]-7-氧杂双环[2.2.1]庚-2-基]-5-庚烯酸(SQ31,491)的一种新的生物素化衍生物1-[[1S-[1α,2α(Z),3α,4α]]-7-[3-[[[[(1-氧代环己基丙基)氨基]乙酰基]氨基]甲基]-7-氧杂双环[2.2.1]庚-2-基]-5-庚烯酰基]-2-[六氢-2'-氧代-1H-噻吩并[3',4'd]咪唑-4'-戊酰基]肼(SQB)的合成、生物学评价及应用。SQB通过使SQ31,491与生物素酰肼反应合成,产物通过快速柱色谱法纯化。发现SQB能特异性抑制U46619诱导的血小板聚集,IC50为275 nM。另一方面,SQB不抑制二磷酸腺苷或A23187诱导的聚集。竞争结合研究表明,SQB在3-[(3-胆酰胺丙基)二甲基铵]-1-丙烷磺酸盐(CHAPS)增溶的血小板膜中对[3H]-[1S-[1α,2β(5Z),3β,4α]]-7-[3-[[2[(苯氨基)羰基]肼基]甲基]-7-氧杂双环[2.2.1]庚-2-基]-5-庚烯酸([3H]SQ29,548)的特异性结合产生浓度依赖性抑制,Ki为220 nM。SQB抑制结合曲线的形状与TXA2/PGH2受体拮抗剂BM13.177产生的曲线无法区分。最后,用SQB和异硫氰酸荧光素(FITC)-抗生物素蛋白孵育凝胶过滤血小板或富含血小板血浆,证明血小板质膜TXA2/PGH2受体有荧光标记。此外,血小板与TXA2/PGH2拮抗剂SQ29,548共同孵育可显著降低这种SQB-FITC荧光标记。基于SQB-FITC-抗生物素蛋白标记完整血小板的能力,可以得出以下结论:(1)血小板TXA2/PGH2受体的一部分存在于质膜中;(2)这些受体的结合域位于外膜表面或其附近。总体而言,这些数据表明SQB是TXA2/PGH2受体的高度特异性探针,对血小板和其他组织中的受体定位研究具有重要价值。